Pseudoangiomatous stromal hyperplasia of the breast: Clinical evaluation.

Breast disease Pub Date : 2023-01-01 DOI:10.3233/BD-220070

Ahmet Cem Esmer, Deniz Tazeoglu, Ahmet Dag

{"title":"Pseudoangiomatous stromal hyperplasia of the breast: Clinical evaluation.","authors":"Ahmet Cem Esmer, Deniz Tazeoglu, Ahmet Dag","doi":"10.3233/BD-220070","DOIUrl":null,"url":null,"abstract":"Background: Pseudoangiomatous stromal hyperplasia is a rare benign breast stromal proliferative lesion of the breast. Clinical presentation ranges from rapidly growing mass to incidental identification in routine screening. This difference in manifestation and its rarity makes it difficult to be a standard treatment protocol. Therefore, we aimed to share our clinical experience in Pseudoangiomatous stromal hyperplasia.Methods: The files of patients who underwent core biopsy or surgical excision due to a breast mass and resulted in pseudoangiomatous stromal hyperplasia between January 2013 and December 2021 were included in the study.Results: 17 patients with a median age of 37 (22-68) were found Pseudoangiomatous stromal hyperplasia confirmed by surgical excision or core biopsy. Chosen treatment option was observation in 8 patients (47.1%), while surgical excision was used in 9 (52.9%) patients. The mean follow-up period was 55.24 ± 26.72 (13-102) months. None of the patients observed the Malignant transformation during the follow-up period.Conclusion: For Pseudoangiomatous Stromal Hyperplasia of the breast, surgical excision with clean margins or close follow-up after diagnosis confirmation by tissue biopsy is sufficient. Pseudoangiomatous Stromal Hyperplasia is not a risk factor for developing breast cancer.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"115-119"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-220070","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Pseudoangiomatous stromal hyperplasia is a rare benign breast stromal proliferative lesion of the breast. Clinical presentation ranges from rapidly growing mass to incidental identification in routine screening. This difference in manifestation and its rarity makes it difficult to be a standard treatment protocol. Therefore, we aimed to share our clinical experience in Pseudoangiomatous stromal hyperplasia.

Methods: The files of patients who underwent core biopsy or surgical excision due to a breast mass and resulted in pseudoangiomatous stromal hyperplasia between January 2013 and December 2021 were included in the study.

Results: 17 patients with a median age of 37 (22-68) were found Pseudoangiomatous stromal hyperplasia confirmed by surgical excision or core biopsy. Chosen treatment option was observation in 8 patients (47.1%), while surgical excision was used in 9 (52.9%) patients. The mean follow-up period was 55.24 ± 26.72 (13-102) months. None of the patients observed the Malignant transformation during the follow-up period.

Conclusion: For Pseudoangiomatous Stromal Hyperplasia of the breast, surgical excision with clean margins or close follow-up after diagnosis confirmation by tissue biopsy is sufficient. Pseudoangiomatous Stromal Hyperplasia is not a risk factor for developing breast cancer.

查看原文本刊更多论文

乳腺假性血管瘤间质增生:临床评价。

背景:假性血管瘤间质增生是一种罕见的乳腺良性间质增生性病变。临床表现从快速增长的肿块到在常规筛查中偶然发现。这种表现上的差异及其罕见性使其难以成为标准的治疗方案。因此，我们希望在此分享我们治疗假性血管瘤间质增生的临床经验。方法:纳入2013年1月至2021年12月期间因乳腺肿块接受核心活检或手术切除并导致假性血管瘤间质增生的患者档案。结果:17例患者中位年龄为37岁(22-68岁)，经手术切除或核心活检证实为假性血管瘤间质增生。选择的治疗方案为观察8例(47.1%)，手术切除9例(52.9%)。平均随访时间55.24±26.72(13-102)个月。随访期间未见恶性转化。结论:对于乳腺假性血管瘤性间质增生，经组织活检确认诊断后，行边缘清洁的手术切除或密切随访即可。假性血管瘤间质增生不是发生乳腺癌的危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.